Bronchioloalveolar carcinoma: a review of the epidemiology, pathology, and treatment.
Bronchioloalveolar carcinoma (BAC) is an important subtype of pulmonary adenocarcinoma. It has received increasing attention in recent years, due to its increasing incidence and its rate of sensitivity to epidermal growth factor-tyrosine kinase inhibitors (EGFR-TKIs). This article reviews the epidemiology, risk factors, pathology, clinical presentation, and treatment of this disease. Special focus is paid to the emerging role of oral EGFR-TKIs in Bronchioloalveolar cell carcinoma.
Jackman
David M
DM
Dana Farber Cancer Institute, Boston, MA 02115, USA.
Chirieac
Lucian R
LR
Jänne
Pasi A
PA
D002282:Adenocarcinoma, Bronchiolo-Alveolar / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D000970:Antineoplastic Agents / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors; D006801:Humans; D015994:Incidence; D008175:Lung Neoplasms / Q000453:epidemiology / Q000473:pathology / Q000628:therapy; D011379:Prognosis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D012307:Risk Factors
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors